<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="block">
<roleset id="block.01" name="" wordnet="3">
<roles>
  <role n="0" descr="causer agent
"/>
  <role n="1" descr="theme (process or entity being stopped)
"/>
</roles>
<example src="MEDLINE" no="*1">
<text>
Mutations at the 3' splice site that specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3' splice site.

</text>
       <arg n="0">Mutations at the 3' splice site
</arg>
       <arg n="1">step II
</arg>
<fdg>
1	Mutations	mutation		@NH %NH N NOM PL	@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL
2	at	at	mod:&gt;1	@&lt;NOM %N&lt; PREP
3	the	the	det:&gt;6	@DN&gt; %&gt;N DET
4	3	3	qn:&gt;6	@QN&gt; %&gt;N NUM CARD
5	&apos;	&apos;
6	splice	splice	pcomp:&gt;2	@&lt;P %NH N NOM SG
7	site	site	subj:&gt;11	@SUBJ %NH N NOM SG
8	that	that	subj:&gt;10	@SUBJ %NH &lt;Rel&gt; PRON
9	specifically	specifically		@AD-A&gt; %E&gt; ADV
10	block	block	mod:&gt;7	@+FMAINV %VA V PRES
11	step	step		@+FMAINV %VA V PRES
12	II	ii	frq:&gt;15	@ADVL %EH NUM ORD
13	do	do	v-ch:&gt;15	@+FAUXV %AUX V PRES
14	not	not	neg:&gt;13	@ADVL %EH NEG-PART
15	affect	affect		@-FMAINV %VA V INF
16	the	the	det:&gt;17	@DN&gt; %&gt;N DET
17	association	association	obj:&gt;15	@OBJ %NH N NOM SG
18	of	of	mod:&gt;17	@&lt;NOM-OF %N&lt; PREP
19	hPrps	hprp	pcomp:&gt;18	@&lt;P %NH &lt;?&gt; N NOM PL
20	16	16	mod:&gt;19	@&lt;NOM %N&lt; NUM CARD
21	and	and	cc:&gt;20	@CC %CC CC
22	17	17	cc:&gt;20	@&lt;NOM %N&lt; NUM CARD
23	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
24	the	the	det:&gt;25	@DN&gt; %&gt;N DET
25	spliceosome	spliceosome	pcomp:&gt;23	@&lt;P %NH &lt;?&gt; N NOM SG
26	,	,
27	indicating	indicate	ha:&gt;15	@-FMAINV %VA ING
28	that	that	pm:&gt;32	@CS %CS CS
29	these	this	det:&gt;30	@DN&gt; %&gt;N DET DEM PL
30	factors	factor	subj:&gt;31	@SUBJ %NH N NOM PL
31	may	may	v-ch:&gt;32	@+FAUXV %AUX V AUXMOD
32	function	function	obj:&gt;27	@-FMAINV %VA V INF
33	at	at	loc:&gt;32	@ADVL %EH PREP
34	a	a	det:&gt;35	@DN&gt; %&gt;N DET SG
35	stage	stage	pcomp:&gt;33	@&lt;P %NH N NOM SG
36	of	of	mod:&gt;35	@&lt;NOM-OF %N&lt; PREP
37	step	step	attr:&gt;38	@A&gt; %&gt;N N NOM SG
38	II	ii	pcomp:&gt;36	@&lt;P %NH NUM ORD
39	prior to	prior to	mod:&gt;38	@&lt;NOM %N&lt; PREP
40	recognition	recognition	pcomp:&gt;39	@&lt;P %NH N NOM SG
41	of	of	mod:&gt;40	@&lt;NOM-OF %N&lt; PREP
42	the	the	det:&gt;45	@DN&gt; %&gt;N DET
43	3	3	qn:&gt;45	@QN&gt; %&gt;N NUM CARD
44	&apos;	&apos;
45	splice	splice	pcomp:&gt;41	@&lt;P %NH N NOM SG
46	site	site		@SUBJ %NH N NOM SG
47	.     .
</fdg>
</example>
<example src="EMBO" no="*1">
<text>
Tagetin is more specific for distinguishing between different RNA polymerases because it blocks RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.

</text>
       <arg n="0">Tagetin
</arg>
       <arg n="1">RNA polymerase during elongation
</arg>
<fdg>
1	Tagetin	tagetin	subj:&gt;2	@SUBJ %NH &lt;?&gt; N NOM SG
2	is	be	main:&gt;0	@+FMAINV %VA V PRES SG3
3	more	much	ad:&gt;4	@AD-A&gt; %E&gt; ADV CMP
4	specific	specific	comp:&gt;2	@PCOMPL-S %NH A ABS
5	for	for	mod:&gt;4	@&lt;NOM %N&lt; PREP
6	distinguishing	distinguish	pcomp:&gt;5	@&lt;P-FMAINV %VA ING
7	between	between	ha:&gt;6	@ADVL %EH PREP
8	different	different	attr:&gt;9	@A&gt; %&gt;N A ABS
9	RNA	rna	attr:&gt;10	@A&gt; %&gt;N ABBR NOM SG
10	polymerases	polymerase	pcomp:&gt;7	@&lt;P %NH N NOM PL
11	because	because	pm:&gt;13	@CS %CS CS
12	it	it	subj:&gt;13	@SUBJ %NH PRON NOM SG3
13	blocks	block	cnt:&gt;2	@+FMAINV %VA V PRES SG3
14	RNA	rna	attr:&gt;15	@A&gt; %&gt;N ABBR NOM SG
15	polymerase	polymerase	obj:&gt;13	@OBJ %NH N NOM SG
16	during	during	ha:&gt;13	@ADVL %EH PREP
17	elongation	elongation	pcomp:&gt;16	@&lt;P %NH N NOM SG
18	(	(
19	Mathews	mathews	main:&gt;18	@APP %NH &lt;?&gt; N NOM SG
20	and	and		@CC %CC CC
21	Durbin	durbin		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@APP %NH N NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
22	,	,
23	1994	1994		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
24	)	)
25	,	,
26	i.e.	i.e.	meta:&gt;29	@ADVL %EH ADV
27	its	it	attr:&gt;28	@A&gt; %&gt;N PRON GEN SG3
28	action	action	subj:&gt;29	@SUBJ %NH N NOM SG
29	is	be		@+FMAINV %VA V PRES SG3
30	independent	independent	comp:&gt;29	@PCOMPL-S %NH A ABS
31	of	of	mod:&gt;30	@&lt;NOM-OF %N&lt; PREP
32	different	different	attr:&gt;33	@A&gt; %&gt;N A ABS
33	initiation	initiation		@SUBJ %NH N NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
34	factors	factor		@+FMAINV %VA V PRES SG3	@&lt;P %NH N NOM PL
35	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine blocks agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).

</text>
       <arg n="0">staurosporine
</arg>
       <arg n="1">agrin-induced AChR clustering and phosphorylation
</arg>
<fdg>
1	A	a	det:&gt;3	@DN&gt; %&gt;N DET SG
2	downstream	downstream	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	kinase	kinase	subj:&gt;4	@SUBJ %NH N NOM SG
4	appears	appear		@+FMAINV %VA V PRES SG3
5	to	to	pm:&gt;6	@INFMARK&gt; %AUX INFMARK&gt;
6	be	be	comp:&gt;4	@-FMAINV %VA V INF
7	essential	essential	comp:&gt;6	@PCOMPL-S %NH A ABS
8	for	for	mod:&gt;7	@&lt;NOM %N&lt; PREP
9	agrin	agrin	pcomp:&gt;8	@&lt;P %NH N NOM SG
10	-	-
11	mediated	mediate		@-FMAINV %VP EN
12	signaling	signal	obj:&gt;11	@-FMAINV %VA ING
13	,	,
14	since	since	pm:&gt;16	@CS %CS CS
15	staurosporine	staurosporine	subj:&gt;16	@SUBJ %NH &lt;?&gt; N NOM SG
16	blocks	block	cnt:&gt;12	@+FMAINV %VA V PRES SG3
17	agrin	agrin	obj:&gt;16	@OBJ %NH N NOM SG
18	-	-
19	induced	induced		@A&gt; %&gt;N A ABS	@+FMAINV %VA V PAST
20	AChR	achr		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG	@A&gt; %&gt;N N NOM SG
21	clustering	cluster		@-FMAINV %VA ING	@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG
22	and	and		@CC %CC CC
23	phosphorylation	phosphorylation		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@APP %NH N NOM SG
24	without	without		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
25	inhibiting	inhibit	pcomp:&gt;24	@&lt;P-FMAINV %VA ING
26	MuSK	musk	attr:&gt;27	@A&gt; %&gt;N N NOM SG
27	phosphorylation	phosphorylation	obj:&gt;25	@OBJ %NH N NOM SG
28	(	(
29	Wallace	wallace	main:&gt;28	@APP %NH N NOM SG
30	,	,
31	1994	1994		@NH %NH NUM CARD	@&lt;P %NH NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
32	;	;
33	Fuhrer	fuhrer	main:&gt;32	@NH %NH N NOM SG
34	et	et	cc:&gt;33	@CC %CC CC
35	al.	al.	cc:&gt;33	@NH %NH ABBR NOM SG
36	,	,
37	1997	1997	cc:&gt;35	@NH %NH NUM CARD
38	)	)
39	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
Labeling with antibodies to the Y553 phosphopeptide is specific since labeling is blocked by pre-incubation of the antibodies with the phosphopeptide.

</text>
       <arg n="0">[by] pre-incubation of the antibodies with the phosphopeptide
</arg>
       <arg n="1">labeling
</arg>
<fdg>
1	Labeling	label	subj:&gt;8	@-FMAINV %VA ING
2	with	with	ha:&gt;1	@ADVL %EH PREP
3	antibodies	antibody	pcomp:&gt;2	@&lt;P %NH N NOM PL
4	to	to	mod:&gt;3	@&lt;NOM %N&lt; PREP
5	the	the	det:&gt;7	@DN&gt; %&gt;N DET
6	Y553	y553	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	phosphopeptide	phosphopeptide	pcomp:&gt;4	@&lt;P %NH &lt;?&gt; N NOM SG
8	is	be		@+FMAINV %VA V PRES SG3
9	specific	specific	comp:&gt;8	@PCOMPL-S %NH A ABS
10	since	since		@CS %CS CS	@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
11	labeling	labeling		@PCOMPL-S %NH A ABS	@SUBJ %NH A ABS	@OBJ %NH A ABS	@&lt;P %NH A ABS	@ADVL %EH A ABS
12	is	be	v-ch:&gt;13	@+FAUXV %AUX V PRES SG3
13	blocked	block		@-FMAINV %VP EN
14	by	by	agt:&gt;13	@ADVL %EH PREP
15	pre-	pre-	attr:&gt;16	@A&gt; %&gt;N A ABS
16	incubation	incubation	pcomp:&gt;14	@&lt;P %NH N NOM SG
17	of	of	mod:&gt;16	@&lt;NOM-OF %N&lt; PREP
18	the	the	det:&gt;19	@DN&gt; %&gt;N DET
19	antibodies	antibody	pcomp:&gt;17	@&lt;P %NH N NOM PL
20	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
21	the	the	det:&gt;22	@DN&gt; %&gt;N DET
22	phosphopeptide	phosphopeptide	pcomp:&gt;20	@&lt;P %NH &lt;?&gt; N NOM SG
23	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
Membranes were blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.

</text>
       <arg n="0">-
</arg>
       <arg n="1">Membranes
</arg>
<fdg>
1	Membranes	membrane	subj:&gt;2	@SUBJ %NH N NOM PL
2	were	be	v-ch:&gt;3	@+FAUXV %AUX V PAST PL
3	blocked	block	main:&gt;0	@-FMAINV %VP EN
4	in	in	ha:&gt;3	@ADVL %EH PREP
5	TBST	tbst	pcomp:&gt;4	@&lt;P %NH N NOM SG
6	(	(
7	Tris-buffered	tris-buffered	attr:&gt;8	@A&gt; %&gt;N &lt;?&gt; A ABS
8	saline	saline	main:&gt;6	@APP %NH A ABS
9	,	,
10	0.05%	0.05%	qn:&gt;11	@QN&gt; %&gt;N NUM CARD
11	Tween-20	tween-20	mod:&gt;8	@APP %NH &lt;?&gt; NUM CARD
12	)	)
13	containing	contain		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING
14	5%	5%		@QN&gt; %&gt;N NUM CARD
15	bovine	bovine	attr:&gt;16	@A&gt; %&gt;N A ABS
16	serum	serum	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	albumin	albumin	obj:&gt;13	@OBJ %NH N NOM SG
18	(	(
19	for	for	pm:&gt;22	@CS %CS CS
20	anti-	anti	attr:&gt;21	@A&gt; %&gt;N A ABS
21	phosphotyrosine	phosphotyrosine	subj:&gt;22	@SUBJ %NH &lt;?&gt; N NOM SG
22	blots	blot	mod:&gt;17	@+FMAINV %VA V PRES SG3
23	)	)
24	or	or		@CC %CC CC
25	skimmed	skimmed	attr:&gt;26	@A&gt; %&gt;N A ABS
26	milk	milk		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG
27	and	and	cc:&gt;3	@CC %CC CC
28	probed	probe	cc:&gt;3	@-FMAINV %VP EN
29	with	with	ha:&gt;28	@ADVL %EH PREP
30	antibodies	antibody	pcomp:&gt;29	@&lt;P %NH N NOM PL
31	.     .
</fdg>
</example>
<example src="EMBO" no="5">
<text>
Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 are able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).

</text>
       <arg n="0">antibodies to RAP1
</arg>
       <arg n="1">merozoite invasion in vitro
</arg>
<fdg>
1	Both	both	ad:&gt;2	@AD-A&gt; %E&gt; ADV
2	RAP1	rap1	cc:&gt;4	@SUBJ %NH N NOM SG
3	and	and	cc:&gt;4	@CC %CC CC
4	2	2	subj:&gt;5	@SUBJ %NH NUM CARD
5	are	be	main:&gt;0	@+FMAINV %VA V PRES
6	important	important	attr:&gt;7	@A&gt; %&gt;N A ABS
7	vaccine	vaccine	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	candidates	candidate	comp:&gt;5	@PCOMPL-S %NH N NOM PL
9	because	because	pm:&gt;13	@CS %CS CS
10	it	it	subj:&gt;11	@SUBJ %NH PRON NOM SG3
11	has	have	v-ch:&gt;12	@+FAUXV %AUX V PRES SG3
12	been	be	v-ch:&gt;13	@-FAUXV %AUX EN
13	shown	show	cnt:&gt;5	@-FMAINV %VP EN
14	that	that	pm:&gt;18	@CS %CS CS
15	antibodies	antibody	subj:&gt;18	@SUBJ %NH N NOM PL
16	to	to	mod:&gt;15	@&lt;NOM %N&lt; PREP
17	RAP1	rap1	pcomp:&gt;16	@&lt;P %NH N NOM SG
18	are	be	obj:&gt;13	@+FMAINV %VA V PRES
19	able	able	comp:&gt;18	@PCOMPL-S %NH A ABS
20	to	to	pm:&gt;21	@INFMARK&gt; %AUX INFMARK&gt;
21	block	block	mod:&gt;19	@-FMAINV %VA V INF
22	merozoite	merozoite	attr:&gt;23	@A&gt; %&gt;N &lt;?&gt; N NOM SG
23	invasion	invasion	obj:&gt;21	@OBJ %NH N NOM SG
24	in vitro	in vitro	copred:&gt;21	@A&gt; %&gt;N A ABS
25	(	(
26	Schofield	schofield	main:&gt;25	@APP %NH N NOM SG
27	et	et	cc:&gt;26	@CC %CC CC
28	al.	al.	cc:&gt;26	@APP %NH ABBR NOM SG
29	,	,
30	1986	1986		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@PCOMPL-O %NH NUM CARD	@&lt;NOM %N&lt; NUM CARD
31	;	;
32	Harnyuttanakorn	harnyuttanakorn	mod:&gt;30	@NH %NH &lt;?&gt; N NOM SG
33	et	et	cc:&gt;32	@CC %CC CC
34	al.	al.	cc:&gt;32	@NH %NH ABBR NOM SG
35	,	,
36	1992	1992	cc:&gt;34	@NH %NH NUM CARD
37	;	;
38	Howard	howard	mod:&gt;36	@NH %NH N NOM SG
39	et	et	cc:&gt;38	@CC %CC CC
40	al.	al.	cc:&gt;38	@NH %NH ABBR NOM SG
41	,	,
42	1998a	1998a	cc:&gt;40	@NH %NH NUM CARD
43	)	)
44	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
